Advertisement

Reactions Weekly

, Volume 1777, Issue 1, pp 189–189 | Cite as

Osimertinib/trametinib

Various toxicities along with drug resistance: case report
Case report
  • 15 Downloads

Reference

  1. Dagogo-Jack I, et al. Response to the Combination of Osimertinib and Trametinib in a Patient With EGFR-Mutant NSCLC Harboring an Acquired BRAF Fusion. Journal of Thoracic Oncology 14: e226-e228, No. 10, Oct 2019. Available from: URL: http://doi.org/10.1016/j.jtho.2019.05.046 - USACrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations